NASDAQ:MGTA Magenta Therapeutics (MGTA) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free MGTA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.68▼$0.7650-Day Range$0.36▼$0.7652-Week Range$0.32▼$2.07Volume376,000 shsAverage Volume848,835 shsMarket Capitalization$42.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Magenta Therapeutics alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Magenta Therapeutics Stock (NASDAQ:MGTA)Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. MGTA Stock News HeadlinesMay 21, 2024 | msn.comNew Caledonia riots: Mercy flight leaves Noumea Magenta Aerodrome, more evacuations likely throughout weekMay 15, 2024 | msn.comMalcolm McDowell, Jacob Ward to Lead Vietnam Draft Drama ‘Summerhouse,’ Magenta Light Studios Launching Sales at Cannes (EXCLUSIVE)May 9, 2024 | yahoo.comMagenta Journal announced as the new digital Muskingum University news publicationMay 2, 2024 | msn.comMagenta Mobility And Kuehne+Nagel Partner To Electrify Road Logistics In IndiaApril 22, 2024 | msn.comWhen Red-Hot Isn't Enough: New Government Heat Risk Tool Sets Magenta as Most Dangerous LevelApril 13, 2024 | msn.comWhat's Included In T-Mobile's Magenta Max 55+ Plan (And How It Compares To Others)April 2, 2024 | msn.comMagenta the horse rescued from Fenland river by fire crews after becoming spookedMarch 26, 2024 | seekingalpha.comPSTX Poseida Therapeutics, Inc.March 20, 2024 | seekingalpha.comDNTH Dianthus Therapeutics, Inc.February 23, 2024 | finanznachrichten.deTEOCO's new framework drives Zero Touch Operational Automation at Magenta TelekomFebruary 22, 2024 | finance.yahoo.comTEOCO's New Framework drives Zero Touch Operational Automation at Magenta TelecomFebruary 16, 2024 | msn.comGerman streamer Joyn lands on Magenta TVFebruary 7, 2024 | macrumors.comT-Mobile Debuts 'Magenta Status' Rewards for SubscribersFebruary 7, 2024 | 9to5mac.comT-Mobile ramps up loyalty rewards with ‘Magenta Status’, here’s what’s includedFebruary 7, 2024 | stockhouse.comT-Mobile Customers Now Have "Magenta Status" - VIP Vibes with One-of-a-Kind Benefits Across Premium Brands and ServicesFebruary 3, 2024 | investing.comViking Therapeutics Inc (VKTX)January 31, 2024 | msn.comT-Mobile's Magenta Max Plan: Is It Really Worth Upgrading?November 29, 2023 | msn.comOperation Magenta: Kent Police issue update following Gosport Memorial Hospital investigationNovember 27, 2023 | msn.comMagenta’s Ellesmere Port extra care scheme celebrates sixth birthdayNovember 21, 2023 | health.usnews.comMagenta HallNovember 21, 2023 | msn.comMagenta Living collaborates with Welsh housing associationNovember 20, 2023 | msn.comMovie Review - Magenta Coal: Promising Series Crashlands At Tail EndNovember 16, 2023 | msn.com£3.6m invested into making Magenta Living houses energy efficientNovember 14, 2023 | msn.comEstate of Stan VanDerBeek, Experimental Filmmaker and ‘Agitator,' Joins Magenta PlainsNovember 14, 2023 | finance.yahoo.comFMR LLC Acquires New Stake in Magenta Therapeutics IncSee More Headlines Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 201-2700FaxN/AEmployees67Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.88% Return on Assets-57.27% Debt Debt-to-Equity RatioN/A Current Ratio19.49 Quick Ratio19.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book0.57Miscellaneous Outstanding Shares60,665,000Free Float51,456,000Market Cap$42.44 million OptionableNot Optionable Beta2.12 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 51)MBA, Pres, Chief Financial & Operating Officer and Treasurer Comp: $637.21kShan WuHead of Investor RelationsMr. Thomas W. Beetham J.D. (Age 53)MBA, Chief Legal Officer & Sec. Ms. Catherine MonaghanHead of Clinical Devel. OperationsMr. Jim HaneySr. Director of Investor RelationsKey CompetitorsLianBioNASDAQ:LIANBioLineRxNASDAQ:BLRXPHAXIAM TherapeuticsNASDAQ:PHXMPolarityTENASDAQ:PTEIQ9 Meters BiopharmaNASDAQ:NMTRView All Competitors MGTA Stock Analysis - Frequently Asked Questions How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02. When did Magenta Therapeutics' stock split? Magenta Therapeutics shares split on Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly created shares were payable to shareholders after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What is Jason Gardner's approval rating as Magenta Therapeutics' CEO? 3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP). When did Magenta Therapeutics IPO? Magenta Therapeutics (MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:MGTA) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Magenta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.